ConvaTec Group PLC Scrip Dividend - calculation price (7388A)

TIDMCTEC

RNS Number : 7388A

ConvaTec Group PLC

13 September 2018

Scrip Dividend - calculation price

Reading, United Kingdom (13 September 2018)

On 1 August 2018 ConvaTec Group Plc ("ConvaTec" or "the Company") declared an interim dividend of 1.717 cents per share (the "interim dividend"). This interim dividend is to be paid on 12 October 2018 to shareholders on the share register as at 7 September 2018 ("record date"). The dividend is payable in cash in sterling to holders of ordinary shares, the chosen exchange rate for this payment is $1.312/GBP1.00, determined on 1 August 2018, giving a total sterling dividend of GBP25,669,593.70. On 2 August 2018 the Company announced that a scrip dividend will be made available for this interim dividend allowing shareholders to elect to receive their dividend in the form of new ordinary shares.

The "Calculation Price" for the issue of new ordinary shares under the scrip dividend scheme is:

228.08 pence for each new ordinary share

This is equivalent to 1 new share for approximately 174.28 shares held prior to the ex-dividend date of 6 September 2018

The Calculation Price is the average of the middle market quotations of a ConvaTec share, derived from the London Stock Exchange Daily Official List, for the five consecutive business days from 6 September to 12 September 2018 (inclusive).

The latest date for receipt of elections to participate in the scrip dividend scheme for this interim dividend is 21 September 2018. Shareholders must return their mandate form by 5pm (GMT) or otherwise input their CREST elections to be received by the Company's registrar, Computershare, by 3pm (GMT) on 21 September 2018. Elections received after this deadline will apply to subsequent dividends only. Unless revoked by you, your scrip dividend election will apply for all future dividends for which a scrip dividend is offered. Evergreen elections for CREST shareholders cannot be accepted and elections will revert to cash by default after the payment of each dividend.

Details of the scrip dividend scheme are available at www.convatecgroup.com/investors.

TIMETABLE

Key dates in respect of the scrip dividend scheme for the interim dividend are:

 
  Ex-dividend Date                                                         6 September 2018 
  Record Date                                                              7 September 2018 
  Scrip calculation price determined                                    6-12 September 2018 
                                                                                (inclusive) 
  Scrip calculation price available and announced                         13 September 2018 
  Mandate delivery deadline for Shares held                       3.00 p.m. on 21 September 
   in uncertificated form                                                              2018 
  Mandate delivery deadline for Shares held                       5.00 p.m. on 21 September 
   in certificated form                                                                2018 
  Announcement of the total amount of new shares                          28 September 2018 
   to be issued 
  Dividend payment date                                                     12 October 2018 
 Dispatch of statement in accordance with section                           12 October 2018 
  7 of Scheme Rules and share certificates, CREST 
  accounts credited/updated, and first day of 
  dealings in New Shares 
 

Enquiries

Media

   Bobby Leach, VP Group Corporate Affairs, ConvaTec                    [phone] 

Alastair Elwen, Finsbury [phone]

Analysts and Investors

   John Crosse, VP Investor Relations, ConvaTec                             [phone] 
   Kirsty Law, Director Investor Relations, ConvaTec                         [phone] 

[e-mail]

   LEI:   213800LS272L4FIDOH92 

About ConvaTec

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com where a copy of this announcement can also be found.

# # #

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DIVFKNDPQBKDPCD

(END) Dow Jones Newswires

September 13, 2018 11:00 ET (15:00 GMT)